GENEVA—Findings from the retrospective EURAF study suggest that many patients with BRAF-mutant lung cancers could benefit from treatment with BRAF inhibitors, although specific studies need to be done to confirm this. Data presented at the European Lung Cancer Conference by Oliver Gautschi MD, a medical oncologist from Lucern Cantonal Hospital, Switzerland, found that off-label use of melanoma medicines targeting BRAF achieved significant response rates in patients with advanced non-small cell lung cancer. He discussed the clinical potential of these drugs in lung cancer with Oncology Times reporter Peter Goodwin.
You may also like...
Malaria—Insecticide Research Promises To Beat Mosquito Resistance 2 Jan, 2012 Schistosomiasis: sanitation plus free drug supplies bring hope of elimination 27 Nov, 2012 Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically 9 Aug, 2013 Circulating Free Tumor DNA—Highly Specific, Moderately Sensitive For EGFR Mutation Testing in Lung Cancer 27 Apr, 2015
- Previous story New Drug for Patients with EGFR-TKI-resistant Advanced Non-Small Cell Lung Cancer
- Next story Lack of EGFR Mutation Test Results Before Starting First Line Therapy for Advanced Lung Cancer Worsens Outcomes
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014